Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.

Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.

<h4>Background</h4>Pembrolizumab is currently approved as a first-line therapy for advanced non-small cell lung cancer (NSCLC) patients with a programed death ligand-1 (PD-L1) expression ≥50%. However, the association between the efficacy of pembrolizumab and PD-L1 expression levels in p...

Full description

Bibliographic Details
Main Authors: Ryuya Edahiro, Masaki Kanazu, Hiroyuki Kurebe, Masahide Mori, Daichi Fujimoto, Yoshihiko Taniguchi, Hidekazu Suzuki, Katsuya Hirano, Toshihide Yokoyama, Mitsunori Morita, Yasushi Fukuda, Junji Uchida, Takeshi Makio, Motohiro Tamiya
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0220570

Internet

https://doi.org/10.1371/journal.pone.0220570

Similar Items